Two new studies show that bevacizumab and aflibercept can reduce macular edema and improve visual acuity in patients with central retinal vein occlusion (CRVO). The two drugs block vascular endothelial growth factor (VEGF), as appeared in Ophthalmology.
Visual acuity in the bevacizumab group improved by a mean of 7.5 letters at 6 weeks. 11.4 letters at 12 weeks, 13.9 letters at 18 weeks, and 14.1 letters at 24 weeks. More patients in the bevacizumab group had no residual edema at 24 weeks.
In a second study using aflibercept, at week 24 56.1% of eyes treated had gained 15 letters or more from baseline. Macular edema declined to a significantly greater extent with aflibercept than with a sham treatment.